Drug Most Active Stocks: Pfizer Inc. (NYSE:PFE), Merck & Co. Inc. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Novogen Limited (NASDAQ:NVGN), NanoViricides, Inc. (NYSEMKT:NNVC)

Pfizer Inc., (NYSE:PFE) and Synthon, have entered into an agreement whereby Pfizer has acquired the exclusive commercialisation rights in the United States to glatiramer acetate, a potential generic version of the originator medicine Copaxone for the treatment of relapsing remitting multiple sclerosis (RRMS). Pfizer Inc. (NYSE:PFE) belongs to Healthcare sector. Its net profit margin is 18.50% and weekly performance is 2.15%. On last trading day company shares ended up $36.11. Pfizer Inc. (NYSE:PFE) distance from 50-day simple moving average (SMA50) is 4.86%.

On 31st July, Merck & Co. Inc. (NYSE:MRK) said that its investigational Ebola vaccine candidate, rVSV-ZEBOV, was found to have 100 percent efficacy in an analysis of interim data from a Phase 3 ring vaccination trial in Guinea. Preliminary conclusions from this study, which is continuing, were published on-line today in The Lancet. Merck & Co. Inc. (NYSE:MRK) shares decreased -0.59% in last trading session and ended the day at $58.70. MRK Gross Margin is 69.20% and its return on assets is 9.70%. Merck & Co. Inc. (NYSE:MRK) quarterly performance is -2.22%.

On 27 July, it was reported Competition Commission has cleared Johnson & Johnson (NYSE:JNJ)’s proposed joint venture with Google in the area of surgical robotics. The collaboration between healthcare major Johnson & Johnson (J&J) and Internet giant Google for developing new technologies was announced in March this year. On 04 August, Johnson & Johnson (NYSE:JNJ) shares decreased -0.22% and was closed at $99.80. JNJ EPS growth in last 5 year was 5.30%. Johnson & Johnson (NYSE:JNJ) year to date (YTD) performance is -3.19%.

Novogen Limited (NASDAQ: NVGN) announced it had taken steps to augment the Company’s dominant intellectual property position on its anti-tropomyosin (ATM) technology platform with the lodgement of final specifications for two new patents covering its pioneering platform. Novogen Limited (NASDAQ:NVGN) ended the last trading day at $2.88. Company weekly volatility is calculated as 9.32% and price to cash ratio as 28.38. Novogen Limited (NASDAQ:NVGN) showed a weekly performance of -20.44%.

On July 21, 2015, NanoViricides, Inc. (NYSEMKT:NNVC) entered into employment agreements with Anil Diwan, PhD, the Registrant’s founder, President and Chairman, and Eugene Seymour, MD, MPH, the Registrant’s Chief Executive Officer and Director effective July 1, 2015. NanoViricides, Inc. (NYSEMKT:NNVC) shares decreased -6.25% in last trading session and ended the day at $1.35. NNVC return on assets is -12.30%. NanoViricides, Inc. (NYSEMKT:NNVC) quarterly performance is -23.73%.

Leave a Reply

Your email address will not be published. Required fields are marked *